Center for American Progress

Medicare’s Drug Payment Proposal Puts Patients First
In the News

Medicare’s Drug Payment Proposal Puts Patients First

Zeke Emanuel and Maura Calsyn write about the Medicare Drug Payment Proposal's focus on patients.

A patient in your average doctor’s office, Ms. Myers, has rheumatoid arthritis. Her physician, Dr. Jones, administers an injectable immunotherapy drug, Remicade, as her treatment. Medicare pays Dr. Jones 106 percent of the average sales price (ASP) for the drug, which comes to more than $3,000 every two months. The extra six percent is supposed to cover the drug’s ordering, tracking, storing, and processing, as well as to account for the variation in prices that drug companies charge different doctors.

Commission-type arrangements might sound like something you’d only see for sales positions-especially in the retail or automotive industries, where many companies pay sales personnel a percentage of sales in order to incentivize greater sales volumes and sales of higher priced items.

The above excerpt was originally published in The Huffington Post. Click here to view the full article.

The positions of American Progress, and our policy experts, are independent, and the findings and conclusions presented are those of American Progress alone. A full list of supporters is available here. American Progress would like to acknowledge the many generous supporters who make our work possible.


Zeke Emanuel

Senior Fellow

 (Maura Calsyn)

Maura Calsyn

Former Vice President and Coordinator, Health Policy